Focus on LRRK2 inhibition – implications for idiopathic Parkinson’s
A new preclinical study has shown that LRRK2 inhibition in an animal model of Parkinson’s can improve lysosomal health and reduce alpha synuclein accumulation in dopaminergic neurons.